Startseite>>Signaling Pathways>> DNA Damage/DNA Repair>> Nucleoside Antimetabolite/Analogue>>CI 972 (anhydrous)

CI 972 (anhydrous)

Katalog-Nr.GC35693

CI 972 (wasserfrei) ist ein potenter, oral aktiver und kompetitiver Inhibitor der Purinnukleosid-Phosphorylase (PNP) (Ki\u003d0,83 μM), der sich als T-Zell-selektives Immunsuppressivum entwickelt.

Products are for research use only. Not for human use. We do not sell to patients.

CI 972 (anhydrous) Chemische Struktur

Cas No.: 115787-68-3

Größe Preis Lagerbestand Menge
100mg Please Inquire Please Inquire
250mg Please Inquire Please Inquire
500mg Please Inquire Please Inquire

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

CI 972 anhydrous is a potent, orally active, and competitive inhibitor of purine nucleoside phosphorylase (PNP) (Ki=0.83 μM) under development as a T cell-selective immunosuppressive agent[1][2]. Ki: 0.83 μM (PNP)[1]

CI 972 anhydrous (5-150 mg/kg; p.o.) produces dose-dependent elevation of plasma inosine one hour after administration to rats[1].

[1]. Gilbertsen RB, et al. Biochemical and pharmacological properties of CI-972, a novel 9-deazaguanine analog purine nucleoside phosphorylase (PNP) inhibitor. Adv Exp Med Biol. 1991;309A:41-4. [2]. Gilbertsen RB,et al. Selective in vitro inhibition of human MOLT-4 T lymphoblasts by the novel purine nucleoside phosphorylase inhibitor, CI-972. Biochem Biophys Res Commun. 1991 Aug 15;178(3):1351-8.

Bewertungen

Review for CI 972 (anhydrous)

Average Rating: 5 ★★★★★ (Based on Reviews and 29 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for CI 972 (anhydrous)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.